Kim Kundert Joins Virtrial as Vice President of Operations

SCOTTSDALE, Ariz., Oct. 15, 2018 /PRNewswire-PRWeb/ -- Virtrial, a company using an award-winning virtual care platform to transform telehealth in the clinical research industry, has named Kim Kundert as Vice President of Operations.

"I have worked with Kim for over 10 years. She has a great working knowledge of clinical site operations having been involved in over 14,000 trials. When I envisioned rolling out Virtrial's platform, I knew I needed Kim and her expertise on the team" says Mark Hanley, President and CEO of Virtrial.

Kundert, most recently, served as the Senior Vice President of Operations for the largest site network clinical research organization in the world - Radiant Research/Synexus. Kundert was responsible for the operation and performance of 80+ research sites across the US where she helped develop a platform of standardization across the network sites. Kundert was pivotal in the development and growth of the company from 3 sites when she started in 1998 to the 80+ sites she ultimately managed before her departure in late 2017. Prior to starting her career in research, Kundert worked at Barrows Neurological Institute as a neurological care nurse.

"Understanding the clinical research site aspect, I can easily envision how Virtrial's technology will make a big impact on the current state of research trials, from enrollment of more diverse populations of patients, to protocol compliance and retention," says Kundert.

About Virtrial
Virtrial is using the award-winning virtual care platform to transform telehealth in the clinical research industry. Virtrial offers a patient management program that combines video, text, and email for clinical trial sites to easily, efficiently, and conveniently address specific patient and/or study needs. The platform can be used on any device and at any site. The company vision is to replace 25-50% of standard clinical trial visits with virtual visits to create hybrid studies. This model will be best suited for Phase III and IV studies. Virtrial enables higher performance by clinical trial sites, greater accessibility to trials for patients, and improved outcomes for pharmaceutical companies. Working together we can bring better medications to market more quickly. To learn more about Virtrial, visit https://www.virtrial.com.

SOURCE Virtrial